Dec. 17, 2024
WuXi XDC’s Dual-Function Facility XBCM2 Line2 Successfully Commences Operations, Marking a New Era of Integrated Processes
WuXi Biologics
Offering End-to-End Solutions
- About Us
About Us - Services & SolutionsAbout Us
- Investor RelationsAbout Us
- News & ResourcesAbout Us
Press Releases
-
-
Dec. 13, 2024WuXi XDC Honored with “Most Valuable Pharmaceutical and Healthcare Company” and “Best CFO” Awards -
Nov. 21, 2024WuXi XDC Wins the “Top Investor-Picked Companies” Award, Demonstrating Exceptional Investment Value and Competitive Strength -
Nov. 08, 2024WuXi XDC Named Best CDMO Winner at 2024 World ADC Awards -
Oct. 30, 2024WuXi XDC Receives Morningstar Sustainalytics 2024 ESG “Low Risk” Rating -
Oct. 16, 2024WuXi XDC and Phamadule Morimatsu Achieve Milestone with Successful Shipment of ADC Modular Facilities for Singapore Manufacturing Site -
Aug. 20, 2024WuXi XDC Honored on Fortune China’s 2024 TECH 50 List -
Aug. 20, 2024WuXi XDC Reports Strong Business Updates with Superior Financial Results in 1H 2024: Poised for Future Growth -
Aug. 01, 2024A Complex Play: The Essential Role of CMC in ADC Drug Development